EyePoint Pharmaceuticals Stock Forecast, Price & News

-0.22 (-2.29 %)
(As of 04/16/2021 04:00 PM ET)
Today's Range
Now: $9.37
50-Day Range
MA: $10.49
52-Week Range
Now: $9.37
Volume266,547 shs
Average Volume367,813 shs
Market Capitalization$269.30 million
P/E RatioN/A
Dividend YieldN/A
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. The company provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery; and Retisert, a sustained-release implant for the treatment of posterior segment uveitis. It is also developing EYP-1901, a 6-month bioerodible Durasert Vorolanib tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. The company also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
EyePoint Pharmaceuticals logo

Industry, Sector and Symbol

Industry Analytical instruments
Current SymbolNASDAQ:EYPT
Year FoundedN/A



Sales & Book Value

Annual Sales$20.36 million
Book Value$0.77 per share


Net Income$-56,790,000.00
Net Margins-112.23%


Market Cap$269.30 million
Next Earnings Date5/5/2021 (Estimated)


EyePoint Pharmaceuticals, Inc. to Host Earnings Call
March 4, 2021 |
EyePoint Pharma secures $100.1M capital raise
February 3, 2021 |
EYPT Dec 2020 5.000 call
December 16, 2020 |
See More Headlines


Overall MarketRank

1.37 out of 5 stars

Medical Sector

713th out of 2,024 stocks

Analytical Instruments Industry

15th out of 29 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
-0.22 (-2.29 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EYPT News and Ratings via Email

Sign-up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

EyePoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions

Is EyePoint Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EyePoint Pharmaceuticals stock.
View analyst ratings for EyePoint Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than EyePoint Pharmaceuticals?

Wall Street analysts have given EyePoint Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but EyePoint Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 660,700 shares, an increase of 28.1% from the March 15th total of 515,600 shares. Based on an average trading volume of 356,900 shares, the days-to-cover ratio is currently 1.9 days. Currently, 3.2% of the company's shares are short sold.
View EyePoint Pharmaceuticals' Short Interest

When is EyePoint Pharmaceuticals' next earnings date?

EyePoint Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for EyePoint Pharmaceuticals

How were EyePoint Pharmaceuticals' earnings last quarter?

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) released its quarterly earnings data on Wednesday, March, 3rd. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of $0.45 by $1.52. The business had revenue of $7.13 million for the quarter, compared to analysts' expectations of $24.08 million. EyePoint Pharmaceuticals had a negative net margin of 112.23% and a negative trailing twelve-month return on equity of 434.26%.
View EyePoint Pharmaceuticals' earnings history

How has EyePoint Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

EyePoint Pharmaceuticals' stock was trading at $10.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EYPT stock has decreased by 10.8% and is now trading at $9.37.
View which stocks have been most impacted by COVID-19

When did EyePoint Pharmaceuticals' stock split? How did EyePoint Pharmaceuticals' stock split work?

Shares of EyePoint Pharmaceuticals reverse split on the morning of Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 8th 2020. An investor that had 100 shares of EyePoint Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for EYPT?

4 equities research analysts have issued 12 month price targets for EyePoint Pharmaceuticals' shares. Their forecasts range from $8.50 to $25.00. On average, they expect EyePoint Pharmaceuticals' share price to reach $17.88 in the next year. This suggests a possible upside of 90.8% from the stock's current price.
View analysts' price targets for EyePoint Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are EyePoint Pharmaceuticals' key executives?

EyePoint Pharmaceuticals' management team includes the following people:
  • Ms. Nancy S. Lurker, Pres, CEO & Director (Age 64, Pay $736.41k)
  • Mr. George O. Elston, CFO & Head of Corp. Devel. (Age 56, Pay $489.15k)
  • Dr. Jay S. Duker, Chief Strategic Scientific Officer (Age 62, Pay $53k)
  • Dr. Dario A. Paggiarino, Sr. VP & Chief Medical Officer (Age 64, Pay $541.39k)
  • Mr. Said Saim, Chief Technology Officer (Age 63)
  • Mr. Ron I. Honig Esq., Sr. VP, Gen. Counsel & Company Sec.
  • Ms. Jennifer Leonard, Sr. VP of HR & IT
  • Dr. John Weet, Sr. VP of Regulatory
  • Mr. David Scott Jones, Sr. VP & Chief Commercial Officer (Age 54)
  • Dr. Anna Kluczewska, CEO of AION Diagnostics Ltd, Pres of AION Diagnostics Ltd and Director of AION Diagnostics Ltd

Who are some of EyePoint Pharmaceuticals' key competitors?

What other stocks do shareholders of EyePoint Pharmaceuticals own?

What is EyePoint Pharmaceuticals' stock symbol?

EyePoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

How do I buy shares of EyePoint Pharmaceuticals?

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is EyePoint Pharmaceuticals' stock price today?

One share of EYPT stock can currently be purchased for approximately $9.37.

How much money does EyePoint Pharmaceuticals make?

EyePoint Pharmaceuticals has a market capitalization of $269.30 million and generates $20.36 million in revenue each year. The company earns $-56,790,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis.

How many employees does EyePoint Pharmaceuticals have?

EyePoint Pharmaceuticals employs 84 workers across the globe.

What is EyePoint Pharmaceuticals' official website?

The official website for EyePoint Pharmaceuticals is

Where are EyePoint Pharmaceuticals' headquarters?

EyePoint Pharmaceuticals is headquartered at 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472.

How can I contact EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 617-926-5000 or via email at [email protected]

This page was last updated on 4/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.